It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Gene regulation and metabolism are two fundamental processes that coordinate the self-renewal and differentiation of neural precursor cells (NPCs) in the developing mammalian brain. However, little is known about how metabolic signals instruct gene expression to control NPC homeostasis. Here, we show that methylglyoxal, a glycolytic intermediate metabolite, modulates Notch signalling to regulate NPC fate decision. We find that increased methylglyoxal suppresses the translation of Notch1 receptor mRNA in mouse and human NPCs, which is mediated by binding of the glycolytic enzyme GAPDH to an AU-rich region within Notch1 3ʹUTR. Interestingly, methylglyoxal inhibits the enzymatic activity of GAPDH and engages it as an RNA-binding protein to suppress Notch1 translation. Reducing GAPDH levels or restoring Notch signalling rescues methylglyoxal-induced NPC depletion and premature differentiation in the developing mouse cortex. Taken together, our data indicates that methylglyoxal couples the metabolic and translational control of Notch signalling to control NPC homeostasis.
Gene regulation and metabolism co-ordinate self-renewal and differentiation of neural precursors (NPCs) in the developing brain. Here the authors show that methylglyoxal, a glycolytic intermediate metabolite, promotes GADPH-dependent translational repression of Notch1, thereby promoting NPC differentiation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
2 University of Calgary, Department of Medical Genetics, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Biochemistry and Molecular Biology, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.413571.5) (ISNI:0000 0001 0684 7358)
3 University of Calgary, Department of Medical Genetics, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.413571.5) (ISNI:0000 0001 0684 7358)
4 Chongqing Medical University, Institute of Neuroscience, Chongqing, China (GRID:grid.203458.8) (ISNI:0000 0000 8653 0555)
5 University of Calgary, Department of Medical Genetics, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
6 Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); Hospital for Sick Children, Program in Neurosciences & Mental Health, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
7 Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
8 Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Calgary, Department of Medical Genetics, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Biochemistry and Molecular Biology, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.413571.5) (ISNI:0000 0001 0684 7358); Hospital for Sick Children, Program in Neurosciences & Mental Health, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)